Tegra 4 performance crushes current-gen processors







NVIDIA’s (NVDA) next-generation processors won’t be available in devices until later this year, however early benchmarks have revealed that the new chipset will be worth the wait. Engadget ran a variety of benchmark tests on one of the company’s Tegra 4 reference tablets and was left with scores that in some cases nearly quadrupled the performance of older Tegra 3 devices.


[More from BGR: Samsung is just trolling us now, and it’s not alone]






 Tegra 4 performance crushes current gen processors


[More from BGR: Another major security flaw discovered on iPhone [video]]


Tegra 4 Quadrant scores topped out at 16,436 and AnTuTu benchmarks reached over 36,000, both of which more than tripled the performance from comparable Tegra 3 tablets. Perhaps the most impressive result was the 499ms score from the SunSpider test. The Tegra 4 benchmark, which measures web browsing performance, nearly halved Apple’s iPad 4 score of 865ms.


NVIDIA and its partners are scheduled to debut Tegra 4 in smartphones, tablets and the company’s Project Shield gaming device in July.


This article was originally published on BGR.com


Gadgets News Headlines – Yahoo! News





Title Post: Tegra 4 performance crushes current-gen processors
Url Post: http://www.news.fluser.com/tegra-4-performance-crushes-current-gen-processors/
Link To Post : Tegra 4 performance crushes current-gen processors
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

All the Details on Michelle Obama's Oscar Look







Style News Now





02/25/2013 at 12:50 AM ET











Michelle Obama Oscars Gown
Mario Anzuoni/Reuters/Landov


She was one of the few Oscars guests who didn’t sing a tune, dance a few steps or clutch a trophy, but Michelle Obama‘s surprise appearance during Sunday night’s awards show was still one of the most talked-about moments of the broadcast.


The First Lady appeared via video to announce the Best Picture Oscar, looking like she belonged on the Oscars’ Best Dressed List in a glittering custom smoke gray Naeem Khan gown and Sutra Silver at Fragments jewelry. She wore her bangs straight down but pulled the rest of her hair back into a low bun.


Though it would have made our night if she had gotten dressed to the nines just to present the award from the White House, Obama actually was taking a quick break from hosting the Governors Dinner — so no word on what she thought of the Les Misérables performance or Seth MacFarlane’s hosting job.


Tell us: Were you surprised to see Michelle Obama? What did you think of her outfit?


–Alex Apatoff


PHOTOS: SEE MORE FABULOUS OSCAR STYLE HERE!




Read More..

India Ink: Forces of Creation Moving in Unison





Presenting non-Western dances to Western audiences can be a difficult business. If an artist adjusts too much, a deep tradition can flatten into pandering tourist fare. If an artist adjusts too little, fidelity can get in the way of communication; a living art form can come across as a relic.







Andrea Mohin/The New York Times

Bijayini Satpathy, left, and Pavithra Reddy of the Nrityagram Dance Ensemble in “Alap.”












A sortable calendar of noteworthy cultural events in the New York region, selected by Times critics.





The Indian choreographer Surupa Sen negotiates the balance with grace. The sinuous, asymmetrical poses of her Odissi tradition, looking at once immovable and full of motion, disguise complex negotiations with gravity as mere embellishments of line. Similarly, Ms. Sen’s choreography elaborates on classical Odissi style while seeming merely to clarify it.


For 20 years Ms. Sen has worked closely with the dancer Bijayini Satpathy. For 20 years, in fact, the two women have lived in the same village in Southern India, Nrityagram, which is devoted to dance. The concert of duets and solos they’re bringing to the Skirball Center (April 6 to 7) is titled “Samyoga,” which in Sanskrit means “union” or “the conjunction of heavenly bodies.” That’s a fair description of Ms. Sen and Ms. Satpathy dancing together.


There’s a philosophical idea behind the work — the interaction between male and female principles in creation — but it can be appreciated on purely aesthetic and theatrical grounds. The women dance both male and female roles. Suggestions of demons and giant birds blend into abstract shapes, patterns and rhythms. A love spat between gods is presented as human comedy, in motion touched by the divine. And, as at all events presented by the World Music Institute, the live music should be at least as distinguished as the dancing.


Souleymane Badolo takes on the translation challenge from a different angle. Born in Burkina Faso, he started his dancing career there, in a traditional African troupe. Since 1993 he has been experimenting with Western contemporary dance, performing in Africa and Europe, but the first work he presented in New York, after he moved there in 2009, still looked pretty foreign. Telling his story in a mixture of French and his native language, Gurunsi, Mr. Badolo enacted a private ritual, slapping his flesh and clicking his tongue.


Since then it’s been fascinating to watch him adapt to his new home. Working with Reggie Wilson, a New York postmodern choreographer well versed in African dance, Mr. Badolo has become more postmodern and more New York. For his performances at New York Live Arts (April 25 to 27) he’s looking again at legacy, the line from his great-great-grandfather to his son. He’s also creating a piece based on a Gurunsi divination method involving the scattering of cowrie seeds.


Is that so different from Merce Cunningham’s chance practices? Is there such a great distance between Africa and downtown New York?


Read More..

Firefox takes on smartphone powers Apple, Google






SAN FRANCISCO (Reuters) – Mozilla, makers of the popular Firefox Internet browser, is preparing to challenge Google and Apple‘s grip on smartphone software.


A new Firefox operating system for mobile devices is set for a July release after winning the backing of 13 wireless service providers around the globe, including Spain’s Telefonica, China Unicom and America Movil.






Mozilla is betting there’s room for a software developer-friendly mobile platform alongside Apple’s and Google’s Android, which together power the majority of mobile devices on the planet.


The new software is based on open Web standards and is capable of operating on devices with much lower hardware requirements than today’s existing crop of smarpthones, according to Mozilla.


Because the Firefox OS is open-source and Web-based, third-party developers will be free to sell mobile applications without needing to share revenue with Apple or Google.


“There’s a strategic imperative for the industry to have another OS that really is open and supports choice and competition,” said Mozilla’s Senior Vice President of Products, Jay Sullivan.


Mozilla will showcase some of the first hardware devices based on that software at the Mobile World Congress, taking place in Barcelona this week. Among the brands that have signed on to make devices based on Firefox OS are South Korea’s LG, China’s ZTE and Huawei.


Unlike Google and Apple’s operating systems, which are built from proprietary technology, Firefox OS uses the HTML5 standard that Web services are built with. That means anyone familiar with Web programming can create Firefox OS apps.


Whether a smartphone built on Web standards can deliver the kind of performance that consumers expect remains to be seen. Facebook famously stopped using HTML5 to develop its iPhone app last year, with Chief Executive Mark Zuckerberg saying the technology couldn’t deliver acceptable quality and calling a decision to use HTML5 for its app one of Facebook’s “biggest mistakes.”


SIZE MATTERS


Mozilla, a non-profit organization, also faces stiff competition. Google’s Android software, which the company distributes free to phone vendors from Samsung to HTC, had roughly 70 percent share of the worldwide smartphone market in the fourth quarter, according to industry research firm Gartner. Apple, which created the smartphone market with the 2007 launch of the now-iconic iPhone, had a roughly 21 percent share of the market.


“The real barrier here is not necessarily a technical one, it’s scale,” said John Jackson, an analyst with research firm IDC. Mozilla will need to attract large numbers of consumers and app developers if it hopes to avoid the fate of previous mobile operating system hopefuls, such as Palm’s WebOS, now owned by Hewllet-Packard.


But “the world’s computing experiences are going mobile and when they get to the mobile environment, they’re happening on a platform that’s controlled by either Apple or Google,” said Jackson. “There’s a universe of content and service providers that have an interest in seeing a more neutral platform materialize.”


Mozilla will initially look to compete in so-called “emerging economies” in Latin America, Eastern Europe and Asia, where many people still use older phone models and have yet to upgrade to more expensive smartphones that feature touchscreens and high-speed Internet connections.


The first phones will be available this summer in Brazil, Columbia, Poland, Venezuela, Serbia and Spain.


The first Firefox OS phones that Telefonica will offer this summer come with a wholesale price of $ 100. The price that consumers pay for the phone will vary in different markets and depend on whether the phone is offered on a pre-paid basis or comes with a service contract, a Telefonica spokesman said.


Telefonica will eventually offer higher-end Firefox OS phones, and plans to offer Firefox devices in all 25 countries that it operates in by the end of 2014.


(Reporting By Alexei Oreskovic; Editing by Bernard Orr)


Linux/Open Source News Headlines – Yahoo! News





Title Post: Firefox takes on smartphone powers Apple, Google
Url Post: http://www.news.fluser.com/firefox-takes-on-smartphone-powers-apple-google/
Link To Post : Firefox takes on smartphone powers Apple, Google
Rating:
100%

based on 99998 ratings.
5 user reviews.
Author: Fluser SeoLink
Thanks for visiting the blog, If any criticism and suggestions please leave a comment




Read More..

Breaking Dawn - Part 2 Sweeps the Razzies









02/23/2013 at 10:00 PM EST







Taylor Lautner and Mackenzie Foy, in Breaking Dawn – Part 2


Andrew Cooper, SMPSP/Summit


Who's misérable now?

The Twilight Saga: Breaking Dawn – Part 2, Adam Sandler and Rihanna are among the "winners" of the 33rd annual Golden Raspberry Awards – the Razzies – which are not so much handed out as they are thrown at those who are voted as perpetrating Hollywood's worst achievements of the year.

Breaking Dawn – Part 2, the fifth and final installment in Stephenie Meyer's vampire saga, was recognized in seven categories, including worst picture.

The flick's Kristen Stewart was also cited as worst actress; Taylor Lautner, worst supporting actor; Lautner and 12-year-old Mackenzie Foy, worst screen couple; the entire cast, including Robert Pattinson, worst screen ensemble, and Bill Condon, worst director.

In addition, the film, which since opening last November has taken in more than $828 million at the box office, was named worst sequel.

Sandler, who last year monopolized the Razzies – and set a record by winning in 10 categories with the "comedy" Jack & Jill – this year got only two awards: for worst actor of the year and worst screenplay, both for That's My Boy.

Unlike the Oscars, which keep voting tallies a secret and will be handed out Sunday night during a very glamorous event, founder and Head RAZZberry John Wilson announced Razzie recipients Saturday night in the utilitarian Continental Breakfast Room of the Holiday Inn Express Hollywood Walk of Fame hotel, near (and yet so far from) the Dolby Theatre, home of the Academy Awards.

Wilson revealed to the press that although Rihanna, as worst supporting actress in the movie Battleship, won her Razzie by a landslide, worst screenwriter Sandler only beat the authors of Breaking Dawn by a single vote.

It's close shaves like that that really make or break the Razzies.

Breaking Dawn – Part 2 Sweeps the Razzies| Oscars 2013, The Razzies 2013, Movies, Battleship, That's My Boy, News Franchises, Individual Class, Adam Sandler, Kristen Stewart, Rihanna, Robert Pattinson

Adam Sandler, in That's My Boy, and Rihanna, in Battleship

Columbia; Universal

The 85th annual Academy Awards will air live on ABC starting at 7 p.m. ET/4 p.m. PT on Sunday, Feb. 24, from the Dolby Theatre in Hollywood.
Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Investors face another Washington deadline

NEW YORK (Reuters) - Investors face another Washington-imposed deadline on government spending cuts next week, but it's not generating the same level of fear as two months ago when the "fiscal cliff" loomed large.


Investors in sectors most likely to be affected by the cuts, like defense, seem untroubled that the budget talks could send stocks tumbling.


Talks on the U.S. budget crisis began again this week leading up to the March 1 deadline for the so-called sequestration when $85 billion in automatic federal spending cuts are scheduled to take effect.


"It's at this point a political hot button in Washington but a very low level investor concern," said Fred Dickson, chief market strategist at D.A. Davidson & Co. in Lake Oswego, Oregon. The fight pits President Barack Obama and fellow Democrats against congressional Republicans.


Stocks rallied in early January after a compromise temporarily avoided the fiscal cliff, and the Standard & Poor's 500 index <.spx> has risen 6.3 percent since the start of the year.


But the benchmark index lost steam this week, posting its first week of losses since the start of the year. Minutes on Wednesday from the last Federal Reserve meeting, which suggested the central bank may slow or stop its stimulus policy sooner than expected, provided the catalyst.


National elections in Italy on Sunday and Monday could also add to investor concern. Most investors expect a government headed by Pier Luigi Bersani to win and continue with reforms to tackle Italy's debt problems. However, a resurgence by former leader Silvio Berlusconi has raised doubts.


"Europe has been in the last six months less of a topic for the stock market, but the problems haven't gone away. This may bring back investor attention to that," said Kim Forrest, senior equity research analyst at Fort Pitt Capital Group in Pittsburgh.


OPTIONS BULLS TARGET GAINS


The spending cuts, if they go ahead, could hit the defense industry particularly hard.


Yet in the options market, bulls were targeting gains in Lockheed Martin Corp , the Pentagon's biggest supplier.


Calls on the stock far outpaced puts, suggesting that many investors anticipate the stock to move higher. Overall options volume on the stock was 2.8 times the daily average with 17,000 calls and 3,360 puts traded, according to options analytics firm Trade Alert.


"The upside call buying in Lockheed solidifies the idea that option investors are not pricing in a lot of downside risk in most defense stocks from the likely impact of sequestration," said Jared Woodard, a founder of research and advisory firm condoroptions.com in Forest, Virginia.


The stock ended up 0.6 percent at $88.12 on Friday.


If lawmakers fail to reach an agreement on reducing the U.S. budget deficit in the next few days, a sequester would include significant cuts in defense spending. Companies such as General Dynamics Corp and Smith & Wesson Holding Corp could be affected.


General Dynamics Corp shares rose 1.2 percent to $67.32 and Smith & Wesson added 4.6 percent to $9.18 on Friday.


EYES ON GDP DATA, APPLE


The latest data on fourth-quarter U.S. gross domestic product is expected on Thursday, and some analysts predict an upward revision following trade data that showed America's deficit shrank in December to its narrowest in nearly three years.


U.S. GDP unexpectedly contracted in the fourth quarter, according to an earlier government estimate, but analysts said there was no reason for panic, given that consumer spending and business investment picked up.


Investors will be looking for any hints of changes in the Fed's policy of monetary easing when Fed Chairman Ben Bernake speaks before congressional committees on Tuesday and Wednesday.


Shares of Apple will be watched closely next week when the company's annual stockholders' meeting is held.


On Friday, a U.S. judge handed outspoken hedge fund manager David Einhorn a victory in his battle with the iPhone maker, blocking the company from moving forward with a shareholder vote on a controversial proposal to limit the company's ability to issue preferred stock.


(Additional reporting by Doris Frankel; Editing by Kenneth Barry)



Read More..

2 Palestinians Shot in Clashes With Israeli Settlers





JERUSALEM (AP) — Clashes erupted Saturday in the West Bank, with Jewish settlers shooting two Palestinian demonstrators in the northern village of Kusra, an Israeli military official and Palestinian residents said.




The unrest reflected mounting friction in the West Bank, where Palestinians have faced off against Israeli troops in recent weeks in a series of large demonstrations protesting Israel’s control of the territory in general and in solidarity with four prisoners on hunger strikes in Israeli jails.


Also on Saturday, a Palestinian prisoner died in an Israeli jail, an event that is likely to intensify tensions in the area.


In the West Bank skirmish, Helmi Abdul-Aziz, 24, was shot in the stomach by Jewish settlers, Palestinian demonstrators said. They said settlers also shot Mustafa Hilal, 14, in the foot.


An Israeli military official confirmed that two Palestinians had been shot, apparently by settlers, since the Israeli military forces there were not using live ammunition.


Villagers said the clashes began when a group of Jewish settlers encroached on their village lands and fired guns. They said settlers chased a Palestinian farmer and his family off land, prompting the farmer to call on other villagers to confront the settlers, and men on both sides hurled rocks at one another.


In an Israeli jail on Saturday, Arafat Shalish Shahin Jaradat, a Palestinian prisoner, died apparently of a heart attack, according to an Israeli prison services spokeswoman, Sivan Weizman. She said that Mr. Jaradat had not been on a hunger strike.


Israel’s domestic intelligence agency, the Shin Bet, said that Mr. Jaradat, 30, was arrested last week after he was involved in a rock-throwing attack that injured an Israeli citizen. Mr. Jaradat admitted to the charge, as well to another West Bank rock-throwing episode last year, the Shin Bet said.


A Shin Bet spokesman said that Mr. Jaradat had not been beaten during an interrogation.


Read More..

Courtney Lopez: Gia Thinks Our Dog Is Having a Baby




Celebrity Baby Blog





02/22/2013 at 01:00 PM ET



Courtney Lopez: Gia Thinks Dog Having Baby
Denise Truscello/Wireimage


Mario Lopez is a man of his word.


Following a December wedding, the EXTRA host declared he and wife Courtney would get to work expanding their family immediately — and he wasn’t kidding.


In January, the couple discovered they were indeed expecting.


“Mario and I are so excited to add to our family! I found out a month ago and surprised Mario with the good news at breakfast,” Courtney tells PEOPLE.


But the proud parents aren’t the only ones gearing up for a new addition. Big sister Gia Francesca, 2, already has babies on the brain.


“Gia kind of understands that there is a baby in my belly,” Courtney notes. “She also told me our dog Julio has a baby in his belly — so who knows!”

Despite a bumpy start — “I had a rough couple of weeks when I first found out,” she shares — the mom-to-be is feeling better and already sporting quite the blossoming belly. “I am showing so much faster this time around,” she says.


And with warmer weather on the way, Courtney will be swathing her bump in floor-length frocks — but plans on forgoing a few fashion ensembles from her past.


“I love being pregnant in the summer! I live in maxi dresses,” she says. “Looking back at my first pregnancy, there are certain things that I wore and I have no idea why. I looked horrible and I won’t do that again!”


Originally from Pittsburgh, the expectant mama is thrilled to have settled down with her growing family on the West Coast. Her only wish? That her children will one day enjoy a winter wonderland.


“I don’t miss the East Coast at all — especially the humidity,” she explains. “The one thing I do want my children to experience from an early age is snow. There is nothing like being a kid playing in the snow.”


– Anya Leon


Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..